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Abstract
Since their onset, display technologies have proven useful for the selection of antibodies against a variety of targets;
however, most of the antibodies selected with the currently available platforms need to be further modified for their use in
humans, and are restricted to accessible antigens. Furthermore, these platforms are not well suited for in vivo selections. We
present here a novel cell based antibody display platform, which takes advantage of the functional capabilities of T
lymphocytes. The display of antibodies on the surface of T lymphocytes, as a part of a chimeric-immune receptor (CIR)
mediating signaling, may ideally link the antigen-antibody interaction to a demonstrable change in T cell phenotype, due to
subsequent expression of the early T cell activation marker CD69. In this proof-of-concept, an in vitro selection was carried
out using a human T cell line lentiviral-transduced to express a tumor-specific CIR on the surface, against a human tumor
cell line expressing the carcinoembryonic antigen. Based on an effective interaction between the CIR and the tumor
antigen, we demonstrated that combining CIR-mediated activation with FACS sorting of CD69
+ T cells, it is possible to
isolate binders to tumor specific cell surface antigen, with an enrichment factor of at least 10
3-fold after two rounds,
resulting in a homogeneous population of T cells expressing tumor-specific CIRs.
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Introduction
The display of foreign polypeptides and proteins on the surface
of viruses or cells provides an important tool for the engineering of
biomolecules and the analysis of their interactions with binding
partners [1–3]. The microbial surface display technologies for
screening antibody libraries include phage, yeast and bacteria
platforms [4]. Cell-free systems, as ribosomal display, are also
available [4].
Although the above mentioned systems have been successfully
used for the isolation of antibodies, concerns may rise about the
lack of post-translational modifications and proper folding of
selected proteins. In order to allow processing of the displayed
antibody in a eukaryotic environment, screening systems based on
viruses and mammalian cells have been described.
The potential of retroviral display for the generation and
screening of eukaryotic expression libraries has been demonstrat-
ed for small peptides [5,6] and antibodies [3,7]. Remarkably,
antibodies selected from retroviral libraries exhibit CDR
sequences clearly different to those of antibodies selected from
phage libraries [3]. We could hypothesize that these differences
arise from the adaptation of molecular parameters, such as codon
usage, polypeptide folding and resistance to inactivation by
mammalian cell proteases. Although other mammalian cell
surface display platforms have been developed [8–11], such
methods, similar to phage and ribosome display, are enrichment
techniques based purely on physical interactions and require
multiple roundsof selection to be carried out. This is an important
drawback; specially taking into account the limited number of
antibodies that can be screened in a mammalian cell-based
platform
In this report, we describe the design and testing of a
mammalian cell surface display platform in T lymphocytes. The
display of single chain antibodies (scFv) on the surface of T
lymphocytes, as a part of a fusion protein mediating signaling, may
ideally link the interaction of scFvs with their antigen to a
demonstrable change in T cell phenotype, due to subsequent
expression of activation molecules. Chimeric immune receptor
(CIR) genes are composed of a recognition unit attached to the
transmembrane and intracytoplasmic sequences of a signalling
molecule derived either from the f chain of the TCR/CD3
complex or from the c chain associated with some Fc receptors
(FcR) [12]. CIRs enable us to target various types of effector cells
toward any tumor-associated antigen (TAA) for which a suitable
mAb exists [13]. These Ag-selective cell therapies have been
designed to convert therapeutically important TAAs, expressed on
the cell surface, into recruitment points of effector functions, and
to address the goal of MHC- and exogenous cytokine-independent
activation of effector cells, highly restricted to tumor areas. Upon
encountering antigen, the interaction of the grafted CIR triggers
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The utility and effectiveness of the CIR approach have been
demonstrated in a variety of animal models where tumor-specific
CIRs drove the adoptive transferred autologous T lymphocytes to
accumulate at the tumor site in vivo and prevented tumor growth
[13,14].
The platform presented in this paper allows a positive selection
based on both the existence of an effective interaction, and the
expression of the early T cell activation marker CD69. The
surface level of CD69 can be used both as a ‘‘quality control’’ of
antibody interaction, and as a sor t i n gp a r a m e t e r .U s i n gah u m a n
T cell line, gene-modified to express a tumor-specific CIR on
their surface, and a human tumor cell line we demonstrated that
combining CIR-mediated activation with FACS sorting of
CD69
+ T cells, it is possible to isolate binders to tumor specific
cell surface antigen, with an enrichment factor of 10
3-fold after
two rounds.
Results
Construction of a lentiviral vector encoding a tumor-
specific CIR
In order to generate a model for validating a selection platform
based on molecular and cellular events associated with T cell
activation, we constructed the HIV-1 based lentiviral vector
pRRL-aCEA-CIR-IRES-EGFP (Fig. 1A), containing a bicistronic
expression cassette encoding a TCRf-based CIR and EGFP, as
reporter gene. The CIR comprises a human immunoglobulin
signal peptide, a FLAG epitope, and the anti-carcinoembrionyc
antigen (CEA) scFv antibody MFE23 [15], fused to the
transmembrane and cytoplasmic regions of the human TCRf-
chain [16].
The human T cell line Jurkat was used as a model system to
express the anti-CEA CIR and to test their ability to initiate T cell
activation in response to tumor specific cell surface antigen. Jurkat
Figure 1. Schematic representation of lentiviral vector constructs. (A) Control monocistronic vector (pRRL-IRES-EGFP) containing only the
enhanced-green fluorescent protein (EGFP) gene and bicistronic vector (pRRL-aCEA-CIR-IRES-EGFP) containing the chimeric immune receptor (CIR)
gene and the EGFP sequence. LTR, long terminal repeats; DGAG, ATG-deleted group specific antigen; RRE, Rev-responsive cis-acting element; CMV
promoter; ECMV IRES, enceohalomyocarditis virus internal ribosomal entry site. (B) FACS analysis of EGFP expression after transduction of Jurkat cells
with EGFP encoding lentiviral vectors at different MOIs, ranging from 0.25 to 10. (C) FACS analysis of EGFP and cell surface CIR expression after
transduction of Jurkat cells with CIR-EGFP encoding lentiviral vectors at MOI of 1.
doi:10.1371/journal.pone.0007174.g001
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encoding EGFP at different MOIs and flow cytometry analysis was
used to evaluate the level of EGFP expression (Fig. 1B). Since
transduction at low MOIs did not result in a substantial decrease of
theEGFPexpression,JukatcellswereinfectedatMOI1withVSV-G
pseudotyped lentiviral vectors encoding both EGFP alone (EGFP) or
anti-CEA CIR and EGFP (aCEA-CIR-EGFP), to ascertain
expression of a single antibody species per infected cell. Flow
cytometry analysis (Fig. 1C) revealed that in both cases over 95% of
the cells were EGFP
+. Analysis of cell-surface CIR expression
demonstrated than approximately 60% of Jurkata
CEA-CIR-EGFP cells
expressed the FLAG-tagged anti-CEA CIR at detectable levels,
although there was considerable heterogeneity in the absolute levels
of expression (Fig. 1C). The difference between the absolute levels of
EGFP and CIR expression may be due to the different characteristics
a n dl o c a t i o no fb o t hp r o t e i n s .
Antigen-specific activation of T cells expressing tumor-
specific CIRs
We then examinated the activity of the FLAG-tagged anti-CEA
CIR as a functional receptor molecule. Jurkata
CEA-CIR-EGFP cells
could be activated to secrete IL-2, upon antigen-mediated ligation
of their binding domain by plastic immobilized CEA (iCEA) or
membrane-bound CEA (mCEA) (Fig. 2). We next investigated the
expression of the very early activation antigen CD69 in
Jurkata
CEA-CIR-EGFP and Jurkat
EGFP cells co-cultured overnight
in the presence of CEA-negative (HeLa) or CEA-positive
(HeLa
CEA) cells (Fig. 3A). The results of a representative
experiment are shown in Figure 3B. On average CD69
+ cells
accounted for 40610% of Jurkata
CEA-CIR-EGFP cells stimulated
with CEA-positive cells. This result is similar to that observed after
stimulation of Jurkata
CEA-CIR-EGFP cells with plastic immobilized
anti-CD3 mAb (Fig. 3B). In these conditions the peak expression
of cell surface CD69 occurred between 12 and 24 h (data not
shown). Stimulation of Jurkata
CEA-CIR-EGFP and Jurkat
EGFP cells
with plastic immobilized anti-CD3 mAb or stimulation of
Jurkata
CEA-CIR-EGFP cells with HeLa
CEA cells resulted in a marked
increase in EGFP reporter expression as compared to unstimu-
lated cells (data not shown).
We havedemonstrated previously that an anti-NIP CIRis able to
mediate specific recognition of its cognate antigen, either immobi-
lized (NIP-BSA conjugates) or expressed on a cell surface, resulting
in the production of IL-2 by transfected Jurkat T cells [16,17]. The
CIR comprises a human immunoglobulin signal peptide, the anti-
NIP scFv antibody B1.8, fused to the transmembrane and
cytoplasmic regions of the human TCRf-chain [17]. In the current
study, we found consistently that anti-NIP CIR-expressing Jurkat
cells (Jurkata
NIP-CIR) could be specifically triggered, after incubation
with NIP-modified target HeLa cells (HeLa
NIP), to express CD69
(Fig. 3B). The level of CD69 expression was similar than that
observed in the same cell population in response to plastic-
immobilized anti-CD3mAb (Fig. 3B). Importantly, T cell activation
remained strictly antigen-specific with NIP-negative HeLa or
HeLa
CEA cells unable to induce CD69 expression in Jurkata
NIP-
CIR cells (Fig. 3). Jurkat
EGFP cells or Jurkata
NIP-CIR could not be
stimulated by HeLa or HeLa
CEA cells (Fig. 3).
To further demonstrated the specificity of CIR-mediated
activation, CIR-negative parental Jurkat cells or CIR-positive
Jurkat cells (Jurkata
CEA-CIR-EGFP or Jurkata
NIP-CIR) were co
cultured with a panel of human unmodified tumor cell lines
(Fig. 4). Only Jurkata
CEA-CIR-EGFP cells expressed CD69 after co
culturing with CEA-positive MKN45 cells (Fig. 4). Parental Jurkat
cells or anti-NIP CIR-expressing Jurkat cells (Jurkata
NIP-CIR) could
not be activated to express CD69 with any of the tumor cell
lines tested (Fig. 4). Furthermore, the viability of Jurkat
EGFP,
Jurkata
CEA-CIR-EGFP and Jurkata
NIP-CIR cells was not affected
when co-cultured for 16 hours in the presence of different types
of target cells (data not shown).
Antigen-specific activation of T cells expressing tumor-
specific CIRs in the presence of competitor populations
We next studied the effect of competitor non-transduced Jurkat
T cells on T cell activation mediated through the anti-CEA CIR.
Jurkata
CEA-CIR-EGFP cells were cultured on HeLa
CEA monolayers
in the presence of increasing amounts of CIR-negative competitor
Jurkat cells, and the expression of CD69 was analyzed by flow
cytometry (Fig. 5). Our results indicate that in all these conditions
the presence of competitor cells did not affect the CIR-mediated
induction of CD69 expression (Fig. 5). At effector-to-competitor
ratios ranging from 100:1 to 1:100 the percentage of the EGFP
+
cells that expressed CD69 was kept close to 40% regardless of the
number of competitor cells.
Selection and enrichment of T cells expressing tumor-
specific CIRs
To determine whether T cells expressing CIRs on their surfaces
could serve as a platform for screening and isolating binders to
tumor specific cell surface antigen, Jurkata
CEA-CIR-EGFP cells and
CIR-negative non-transduced Jurkat cells (Fig. 6) or CIR-positive
transfected Jurkat cells (Jurkata
NIP-CIR) (Fig. 7) were mixed at
decreasing concentrations of the former, with a total number of
3610
7 and incubated overnight with confluent monolayers of
HeLa
CEA cells, and the sensitivity of the isolation and enrichment
process evaluated. Mixed Jurkat T cells were recovered from the
tumor cell monolayer by EDTA treatment, ficoll purified, washed
twice with medium and incubated with anti-CD69 PE mAb. At a
mixing ratio 1:1000 a single round of selection by direct FACS
sorting of EGFP
+CD69
+ cells, resulted in a two-log enrichment of
anti-CEA CIR expressing Jurkata
CEA-CIR-EGFP cells, from the
background CIR-negative Jurkat cell population (Fig. 6) or CIR-
positive Jurkata
NIP-CIR cells. The sorted Jurkata
CEA-CIR-EGFP/1S
population was propagated and submitted for an additional round
of activation/selection on HeLa
CEA cell monolayers. After staining
with anti-CD69 PE mAb and FACS sorting nearly 100% of the
cells expressed EGFP (Jurkata
CEA-CIR-EGFP/2S). Overall, CIR-
mediated activation of T cells combined with FACS sorting of
CD69-expressing activated T cells resulted in a 10
3 fold-
enrichment in a tandem two-step round of selection.
Figure 2. IL-2 production by Jurkat
EGFP and Jurkata
CEA-CIR-EGFP
cells stimulated either with plastic immobilized anti-CD3 mAb
or target cells (E:T=1:1; HeLa or HeLa
CEA) for 48 hours.
doi:10.1371/journal.pone.0007174.g002
T Cell Antibody Selection
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cells expressing tumor-specific CIRs
After the second round of activation/selection, the selected
population (Jurkata
CEA-CIR-EGFP/2S) was expanded and charac-
terized phenotypic and functionally. Jurkata
CEA-CIR-EGFP/2S cells
showed higher levels of EGFP and cell surface FLAG-tagged anti-
CEA CIRs (with MFI values enhanced ,2-fold) than the initial
Jurkata
CEA-CIR-EGFP cells (Fig. 8A). Jurkata
CEA-CIR-EGFP/2S cells
could be activated to express CD69 or to produce IL-2, upon
interaction with membrane-bound CEA (mCEA) or immobilized
anti-CD3 mAb (Fig. 8B). Sequence analysis of antibody variable
domains of 20 individual clones revealed no differences between
the initial Jurkata
CEA-CIR-EGFP cells and the selected Jurkat
Jurkata
CEA-CIR-EGFP/2S cells with the exception of punctual
one-nucleotide changes, derived from the PCR amplification
(data not shown).
Discussion
In this study, we describe the design and use of a mammalian
display platform to select scFv antibodies on complex mixtures of
antigens expressed on cell surfaces. A limiting step in the selection
by cell panning of phage antibodies is the high background
binding of non-specific phages [4]. To overcome this limitation,
we designed a positive selection method based on the display of
scFv antibodies on the surface of T lymphocytes, in the context of
activating molecules. The use of a chimeric scFv-TCRf receptor
as a display fusion partner may result in gene expression in
successful cases of interaction.
In fact, we demonstrated that upon encountering specific
antigen on tumor cell surface, human T cells harboring anti-tumor
scFv-TCRf receptors are able to undergo specific activation,
including up-regulation of the early T-cell activation marker
CD69. Combining CIR-mediated activation with FACS sorting of
Figure 3. CIR-mediated activation of human T cells. (A) Cell-surface expression of CEACAM5 (CEA) and NIP-modified molecules on HeLa,
HeLa
CEA and HeLa cells labeled with 2.5 mg/mL of the hapten (HeLa
NIP). (B) FACS analysis of CD69 expression by Jurkat
EGFP, Jurkata
CEA-CIR-EGFP and
Jurkata
NIP-CIR stimulated either with immobilized anti-CD3 mAb or target cells (E:T=1:1; HeLa, HeLa
CEA or HeLa
NIP) for 16 hours.
doi:10.1371/journal.pone.0007174.g003
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+ T cells it is possible to detect and purify tumor-specific T
cells with an enrichment factor of at least 10
3-fold after two
rounds. However, the strength of this lymphocyte display platform
does not rely only on the enrichment factor, but in rescuing
functional scFv antibodies capable of forming a functional immune
synapse.
Recent studies have established that multidomain constructs
comprising the signaling region of CD28 in series with the
signaling domain of the TCRf chain (dual scFv-CD28-TCRf
chimeric receptor) mediated enhanced cytokine production, and
preserved cell viability [18]. Dual CIR with optimized spacer
sequences, to provide accessibility and extended orientation, are
ideal for surface display of antibody libraries in T lymphocytes.
In addition to the advantages of all mammalian expression
libraries this novel positive selection T cell–surface display system
avoids the use of elution procedures so that high affinity antibodies
cannot get lost during selection. Furthermore, the interface
between the tumor cell and the CIR-expressing T cell might
allow selecting human antibodies towards their cognate antigens
when present in their natural setup. Antibodies against trans-
membrane cell surface proteins that are difficult to purify in a
native conformation and against epitopes that are not visible with
the current display technologies might benefit from this platform.
The use of lentiviral-based vectors allows to precisely dose
infection rates, ensuring expression of no more than one antibody
per cell. However, one major drawback of antibody screening in
mammalian cells is the relative small number of cells that can be
handled at time. Thus, whereas phage display routinely allows for
the screening of 10
12 clones in a single panning round [2], the
throughput of a mammalian screening procedure in an one-
antibody-per-cell format is in the range of 10
6 to 10
7 clones that
can be analyzed concomitantly [8].
This ‘‘repertoire diversity’’ limitation might be ameliorated
thanks to its better fit to specific scenarios, for example in vivo
selections. Systemicallyadministeredbacteriophages haveto survive
destruction by immune effector mechanisms [19]_which counts for
a fast depletion in vivo_, avoid non-specific adhesion to vessel walls
[20] and avoid sequestration by organ systems such as the Kuppfer
cells[21],thus,diminishing theactualrepertoire sizeatthe ‘‘point of
selection’’ (whether a solid tumor, a disease model, organ-specific
vasculature, etc). In addition phage particles represent an inert
carrier, with void or limited extravasation ability, which allows the
recovery of displayed peptides homing preferentially to the target
tissue due to their binding to tissue-specific vascular receptors [22],
but poses further restrictions for the in vivo selections beyond the
luminal surface of the vasculature. The present platform overcomes
these limitations: unlike viral particles, immune effector cells can
migrate actively and efficiently through microvascular walls, and
penetrating the core of solid tumors. In this context, a repertoire of
systemically administered CIR-display T lymphocytes can move
Figure 4. CIR-mediated activation of human T cells. (A) Cell-surface expression of CEACAM5 (CEA) on HeLa, HT1080, MDA-MB-231 and MKN45
cells. (B) FACS analysis of CD69 expression by Jurkat, Jurkata
CEA-CIR-EGFP and Jurkata
NIP-CIR stimulated either with immobilized anti-CD3 mAb or target
cells (E:T=1:1; HeLa, HT1080, MDA-MB-231 or MKN45) for 16 hours.
doi:10.1371/journal.pone.0007174.g004
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actively towards the site of tissue damage. We could select tumor-
specific T cells as consequence of a process of extravasation,
mediated by cellular adhesion molecules, and of a process of
retention and activation, mediated by the CIR.
Materials and Methods
Cells and culture conditions
293T cells (human embryo kidney epithelia; CRL-11268),
HeLa cells (human cervix carcinoma; CCL-2), HT-1080 cells
(human fibrosarcoma; CCL-121), MKN45 cells (human stomach
adenocarcinoma; JCRB-0254), and MDA-MB231 cells (human
breast adenocarcinoma; HTB-26) were grown in DMEM
supplemented with 10% (vol/vol) heat-inactivated FCS, (Invitro-
gen Life Technologies, Gaithersburg, MD, USA), referred as to
DMEM complete medium (DCM). Jurkat clone E6-1 (TIB-152)
cells were maintained in RPMI-1640 (Invitrogen Life Technolo-
gies) supplemented with heat inactivated 10% FCS, referred as to
RPMI complete medium (RCM). All of these cell lines were
obtained from the American Type Culture Collection (Rockville,
MD, USA). HeLa
CEA cells [23] were grown in RCM supple-
mented with 750 mg/ml G418 (Invitrogen Life Technologies). All
cell lines were routinely screened for the absence of mycoplasm
contamination by PCR using the Mycoplasm Plus TM Primer Set
(Stratagene, Cedar Creek, TX, USA).
Hapten modification of target cells
HeLa cells were extensively washed in PBS, counted, and
adjusted to a concentration of 10
7/mL. A fresh 50 mg/ml solution
of NIP-CAP-Osu (succinimide ester of 3-nitro-4-hydroxy-5-
iodophenylacetic acid spaced with caproic acid) (Sigma Biosci-
ences, St. Louis MO, USA) in dry dimethylformamide was added
to the cell suspension to give a final concentration of 2.5 mg/mL.
The cells were incubated for 1 hour at 37uC and then washed
three times with 15 mL of cold PBS supplemented with 10% FCS.
Antibodies and reagents
The monoclonal antibodies (mAbs) used included: M2 (anti-FLAG,
Sigma Biosciences); 9E10 (anti-c-myc, Abcam, Cambridge, UK),
C6G9 (anti-human CD66e/CEA, Sigma Biosciences); BD1690 (anti-
H I Vp 2 4 ,A b c a m ) ;S P V T 3 b( a n t i - h u m a nC D 3 ,Z y m e d ,S a n
Francisco, CA, USA) and BG5 (biotinylated anti-human IL-2,
Endogen, Woburn, MA, USA). For direct staining, the PE-conjugated
FN50 mAb (anti-human CD69, BD Biosciences, San Jose ´, CA, USA)
was used. The polyclonal antibodies used included: rabbit anti-human
IL2 (Endogen), horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (Fc specific; Sigma Biosciences); PE-conjugated goat
F(ab’)2 fragment anti-mouse IgG (Fcc Fragment Specific, Jackson
Immuno Research, Newmarket, UK); and biotinylated goat anti-HIV
p24 (Abcam). Streptavidin-HRP polymer, human IL-2, and human
Figure 5. Effect of competitor populations on CIR-mediated T
cell activation. CIR-positive Jurkata
CEA-CIR-EGFP effector (E) cells were
stimulated with CEA-positive target cells for 16 hours in the presence of
increasing amounts of CIR-negative Jurkat competitor (C) cells. The
expression of CD69 on E:C ratios ranging from 100:1 to 1:100 was
measured by FACS on pre-activation (left panels) and post-activation
(right panels) mixtures.
doi:10.1371/journal.pone.0007174.g005
Figure 6. Selection of CIR-activated T cells. Jurkata
CEA-CIR-EGFP
effector (E) cells and CIR-negative Jurkat competitor (C) cells at a E:C
mixing ratio 1:1000 were stimulated with CEA-positive target cells for
16 hours and further sorted on the basis of EGFP and CD69 expression.
After a period of cell expansion the activation/selection cycle was
repeated.
doi:10.1371/journal.pone.0007174.g006
T Cell Antibody Selection
PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7174CEA were from Sigma Biosciences and HIV-p24 core protein was
from Jena Bioscience GmbH (Jena, Germany).
Vector construction and preparation of lentiviral vector
stocks
The HIV-derived four-plasmid system was kindly provided by
D. Trono (Department of Microbiology and Molecular Medi-
cine, University of Geneva, Switzerland). The transfer vector
pRRL-IRES-EGFP contains a cytomegalovirus (CMV) promot-
er that drives an enhanced-green fluorescent protein (EGFP)
expression cassette [24]. To construct the vector pRRL-
FLAGaCEA-TCRf-IRES-EGFP, the plasmid pVAC.aNIP-
TCRf was digested with NotI and XbaI to remove a PstI site
and religated to form pVAC.aNIP-TCRf-Not/Xba in which an
oligonucleotide carrying the FLAG sequence (Table 1, oligonu-
cleotides 1 and 2) was introduced between XmaI and PstI to
generate the plasmid pVAC.FLAGaNIP-TCRf-Not/Xba. The
coding sequence was restored by inserting the HindIII/BstEII
fragment from plasmid pVAC.FLAGaNIP-TCRf-Not/Xba into
the HindIII/BstEII digested backbone of plasmid pVAC.a-
NIP.TCRf rendering the plasmid pVAC.FLAGaNIP-TCRf.
The MFE-23 scFv gene (aCEA) was PCR amplified from
pVAC.aCEA-TCRf with primers 3 and 4 (Table 1) and the
sequence was verified using primers 5 and 6. The NheI/NotI-
cleaved PCR fragment was ligated into the NheI/NotI digested
backbone of plasmid pVAC.FLAGaNIP-TCRf to obtain the
plasmid pVAC.FLAGaCEA-TCRf. To aid cloning, a NotI site
was removed from pRRL-IRES-EGFP by digestion using NotI,
blunting and religation (pRRL-IRES-EGFP
NotKO). The FLA-
GaCEA-TCRf coding sequence was PCR amplified from
plasmid pVAC.FLAGaCEA-TCRf with primers 7 and 8
(Table 1), digested with BglII and SalI and subcloned into the
BamHI/XhoI-digested backbone of the plasmid pRRL-IRES-
EGFP
NotKO, obtaining the vector pRRL.FLAGaCEA-TCRf-
IRES-EGFP (called from now pRRL-CIR-IRES-EGFP). Lenti-
viral particles (ACEA-CIR-EGFP and EGFP) were produced by
cotransfection of 293T cells by calcium phosphate precipitation
as described previously [24].
Determination of vector titers
An ELISA directed against the p24 capsid protein was
performed for tittering the physical particles (PP). PP number
was in the range of 1610
7–1610
8 PP/ml in both lentiviral vector
preparations (ACEA-CIR-EGFP and EGFP). Biological titration
was performed as previously described [16]. The infective
particles (transducing units, TU/ml) were 4610
7 TU/ml for the
lentivirus ACEA-CIR-EGFP and 2610
7 TU/ml for the lentivirus
EGFP.
Genetic modification of human T cells
Exponentially growing Jurkat cells (1610
5) were incubated
overnight in 96-well plates with lentiviral stocks (aCEA-CIR-
EGFP or EGFP) at different multiplicities of infection (MOI),
r a n g i n gf r o m0 . 2 5t o1 0i naf i n a lv o l u m eo f2 0 0m lo ft h e i r
appropriate medium. The cells were washed and further cultured
for 48 h. Jurkat cells were transfected with the expression vector
pCEP4/aNIPCD3f [16], using Superfect (Qiagen GmbH,
Hilden, Germany) and selected in RCM with 400 mg/ml
hygromycin B (Invitrogen Life Technologies). Cells were
analyzed for expression of EGFP and CIR (aCEA or aNIP) by
FACS.
Flow cytometry
For phenotypic analysis cells were incubated with appropriate
dilutions of PE-conjugated mAbs or PE-conjugated isotype
negative control for 30 min at 4uC. The expression of
CEACAM5 (CEA) on HeLa, HeLa
CEA, HT1080, MDA-MB-
231 and MKN45 cells was studied as previously described [25].
Cell-surface expression of amino-terminal FLAG-tagged CIR
(aCEA-CIR) was evaluated after incubation of cells with anti-
FLAG mAb followed by incubation with PE-conjugated goat
F(ab’)2 anti-mouse IgG. Cell-surface expression of a-NIP-CIR
was evaluated using a FITC-conjugated goat anti-serum to
mouse l-chain (Southern Biotechnology Associates, Birming-
ham, AL; USA). The relative amount of NIP bound to hapten-
modified HeLa cells (HeLa
NIP)w a se s t i m a t e db yi n d i r e c t
immunofluorescence using saturating amounts of a purified
B1.8 scFv antibody fragment (LAV-17), anti-c-myc mAb and a
PE-conjugated goat F(ab’)2 fragment anti-mouse IgG. All
samples were analyzed using an EPICS XL flow cytometer
(Beckman Coulter).
T-cell activation and selection
Non-transduced Jurkat, Jurkata
CEA-CIR-EGFP or Jurkat
EGFP cells
(10
5/well) were incubated with plastic immobilized CEA (1 mg/
well) or anti-CD3 mAb (1 mg/well) in round-bottom 96-well plates
(BD Biosciences). For small-scale co-culture assays, CIR-positive
(Jurkata
CEA-CIR-EGFP or Jurkata
NIP-CIR), CIR-negative (Jurkat or
Jurkat
EGFP), or mixtures of both effector T cells (5610
4/well) were
incubated with different types of target cells, at various effector to
target ratios. The plates were incubated at 37uCi n5 %C O 2. After
Figure 7. Selection of CIR-activated T cells. Jurkata
CEA-CIR-EGFP
effector (E) cells and CIR-positive Jurkata
NIP-CIR competitor (C) cells at a
E:C mixing ratio 1:1000 were stimulated with CEA-positive target cells
for 16 hours and further sorted on the basis of EGFP and CD69
expression. After a period of cell expansion the activation/selection
cycle was repeated.
doi:10.1371/journal.pone.0007174.g007
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CD69 examined by FACS analysis. Supernatants were harvested
and assayed for IL-2 activity by ELISA.
For medium-scale co-cultures, CIR-positive (Jurkata
CEA-CIR-
EGFP or Jurkata
NIP-CIR), CIR-negative (Jurkat), or mixtures of both
effector (Jurkata
CEA-CIR-EGFP:Jurkat or Jurkata
CEA-CIR-EGFP:Jur-
kata
NIP-CIR
), T cells (3610
7) were incubated on HeLa or HeLa
CEA
monolayers at a 1:1 ratio. After 16 h, cells were harvested with
EDTA (Sigma Biosciences), washed, and then Jurkat cells isolated
by density-gradient centrifugation. Viable cell counts were
determined by trypan blue exclusion. The resultant cells were
stained with PE-conjugated anti-CD69 mAb and EGFP
+CD69
+
populations further isolated by FACS using a FACSVantage cell
sorter (BD Biosciences)
Figure 8. Phenotypic and functional characterization of selected Jurkata
CEA-CIR-EGFP cells. (A) Comparative analysis of EGFP and cell
surface CIR expression of the initial (Jurkata
CEA-CIR-EGFP) and the selected (Jurkata
CEA-CIR-EGFP/2S) cell population after two rounds of activation/
selection on CEA-positive target cells. (B) Comparative analysis of CD69 expression by Jurkata
CEA-CIR-EGFP and Jurkata
CEA-CIR-EGFP/2S cell populations
after stimulation either with immobilized anti-CD3 mAb or target cells (E:T=1:1; HeLa or HeLa
CEA).
doi:10.1371/journal.pone.0007174.g008
Table 1. Oligonucleotide sequences
a.
Name Sequence (59-39)
1 CCGGGGGCCCACTCCGACTACAAAGACGATGACGACAAGGCTAGCCAGGTGCAGCTGCA
2 GCTGCACCTGGCTAGCCTTGTCGTCATCGTCTTTGTAGTCGGAGTGGGCCC
3 GCTAGCCAGGTGCAGCTGCAGCAGTCT
4 CTCTGTAGCGGCCGCCCGTTT
5 CAGGAAACAGCTATGAC
6 TAAAACGACGGCCAG
7 ACAGATCTATGGACTGGACCTGGAGGGT
8 AAATGTCGACTTATTAGCGACGAGGGGGCAG
aSequences of the various oligonucleotides applied for the construction of the vectors, and subsequent verification of vector sequences.
doi:10.1371/journal.pone.0007174.t001
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Total RNA was extracted from unselected and selected
Jurkata
CEA-CIR-EGFP cells with the RNeasy Plus Mini Kit (Qiagen).
cDNA synthesis was performed with cDNA Synthesis Kit for RT-
PCR (AMV) (Roche Diagnostics GmbH, Mannheim, Germany).
The anti-CEA scFv was PCR amplified with primers 4 and 7, and
sequenced with primers 5 and 6 (Table 1).
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